Press Release
MDxHealth to Present Results from Epigenetic Prostate Test to Identify ggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014
IRVINE, CA, and HERSTAL, BELGIUM - January 29, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).
In current standard medical practice PCa prognosis and aggressiveness are mainly guided by Gleason score (GS), as determined on biopsied tissue. However, due to sampling errors biopsied prostate tissue might not be representative of the actual disease. MDxHealth is currently developing an epigenetic prostate cancer test to identify men with aggressive disease and adverse prognosis.
Details of presentation (time is Pacific Standard Time):
Friday, January 31, 2014